Vactosertib

Unknown Manufacturer

Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).

Generate AI report

Overview

Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).

Technical identifiers

Chemical Formula: C₂₂H₁₈FN₇
CAS Number: 1352608-82-2
UNII ID: 6T4O391P5Y

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Application of nicotinamide compounds in preparation of medicine for treating and resisting chordoma
CN 112843058 AApplicant: HUASHAN HOSPITAL FUDAN UNIVPriority: 2021
CN
Application of formamide compound in preparation of drug for resisting spinal cord tumor and kit
CN 112851695 AApplicant: HUASHAN HOSPITAL FUDAN UNIVPriority: 2021
CN
Vactosertib or linivonib and application of combination of Vactosertib and linivonib in preparation of medicine for treating asthma
CN 118976025 AApplicant: UNIV CHINA PHARMAPriority: 2024
CN
TGF-BETA RECEPTOR INHIBITORS FOR USE IN THE THERAPEUTIC TREATMENT OF A PULMONARY FIBROTIC DISEASE
WO 2026104985 A1Applicant: A D A S R LPriority: 2024
WO

Drugs